Clinical trials: sponsored by Akeso
Hepatocellular Carcinoma
A Study of AK112 in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Phase II open label, multicenter study to evaluate the efficacy and safety of AK112 (PD-1/VEGF Bispecific) in patients with unresectable hepatocellular carcinoma (HCC).
- Trial name
- NCT05432492
- Testing
- AK112
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Akeso
Colorectal Cancer
A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer
This is an open label, multicenter Phase Ib/II clinical study on the efficacy and safety of AK119 and AK112 in combination with or without chemotherapy, and AK112 monotherapy in pMMR/MSS CRC
- Trial name
- NCT05846867
- Testing
- AK119, AK112, Oxaliplatin
- Where
- China
- Volunteers
- 170 people
- Sponsor
- Akeso
Hepatocellular Carcinoma
A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)
There're 2 parts in this interventional study: 1. The goal of phase Ib trial is to evaluate the safety and tolerability of AK112 in combination therapies for the purpose of observing the incidence of dose limit toxicity (DLT) as…
- Trial name
- NCT06530251
- Testing
- AK112, Cadonilimab, AK127
- Where
- 2 sites in China
- Volunteers
- 280 people
- Sponsor
- Akeso
Colorectal Adenocarcinoma
AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer
This trial is a Phase III study. The purpose of this study is to evaluate the efficacy and safety of AK112 and chemotherapy versus bevacizumab and chemotherapy for the first-line treatment of metastatic colorectal cancer.
- Trial name
- NCT06951503
- Testing
- AK112, Oxaliplatin, Irinotecan
- Where
- 2 sites in China
- Volunteers
- 560 people
- Sponsor
- Akeso
Pancreatic Cancer
A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer
This is a Phase 3, randomized, double-blind clinical trial aimed at evaluating the efficacy and safety of Ivonescimab plus chemotherapy with or without AK117 versus placebo plus chemotherapy in patients with metastatic pancreatic…
- Trial name
- NCT06953999
- Testing
- Ivonescimab, AK117, Albumin-bound Paclitaxel, Gemcitabine
- Where
- 3 sites in China
- Volunteers
- 999 people
- Sponsor
- Akeso
Gastric / Gastroesophageal Junction Adenocarcinoma
A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or…
- Trial name
- NCT07449780
- Testing
- AK104(SC), AK104(IV), Capecitabine
- Volunteers
- 422 people
- Sponsor
- Akeso
Advanced Malignant Tumors
A Study of AK112 in Advanced Malignant Tumors
Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of AK112 (anti-PD-1 and VEGF bispecific antibody) combined with AK117（Anti-CD47 Antibody）with or without chemotherapy in advanced malignant tumors
- Trial name
- NCT05214482
- Testing
- AK112, AK117, Chemotherapy
- Where
- China
- Volunteers
- 154 people
- Sponsor
- Akeso
Biliary Tract Cancer
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer
There're 2 parts in this interventional study: 1. The goal of phase Ib trial is to evaluate the safety and tolerability of AK130 in combination with AK112 therapy for the purpose of observing the incidence of dose limit toxicity…
- Trial name
- NCT06938321
- Testing
- AK112, AK130
- Where
- China
- Volunteers
- 135 people
- Sponsor
- Akeso
Pancreatic Cancer
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer
This is an open-label, multi-center phase II clinical study consisting of two parts: Part I: To evaluate the safety and efficacy of AK130 combined with AK112 in advanced pancreatic cancer.
- Trial name
- NCT07114315
- Testing
- AK112, AK130
- Where
- 2 sites in China
- Volunteers
- 160 people
- Sponsor
- Akeso
NSCLC
A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC
This is a phase II study. All patients are stage IIIB/C or IV non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- Trial name
- NCT04736823
- Testing
- AK112, Pemetrexed, Paclitaxel
- Where
- China
- Volunteers
- 265 people
- Sponsor
- Akeso
Non-small Cell Lung Cancer
A Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With NSCLC
This trial is a Phase Ib/II study. All patients are stage IIIB/C or IV non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- Trial name
- NCT04900363
- Testing
- AK112
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Akeso
Asthma
A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Asthma
This is a randomized, double-blind phase II clinical study to evaluate the efficacy and safety of AK139 in the treatment of participants with moderate to severe asthma.
- Trial name
- NCT07436221
- Testing
- AK139
- Where
- 2 sites in China
- Volunteers
- 160 people
- Sponsor
- Akeso
Seasonal Allergic Rhinitis
A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Seasonal Allergic Rhinitis
This is a randomized, double-blind phase II clinical study to evaluate the efficacy and safety of AK139 in the treatment of participants with moderate to severe SAR
- Trial name
- NCT07436234
- Testing
- AK139
- Where
- China
- Volunteers
- 111 people
- Sponsor
- Akeso
Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
This study investigates treatment of cadonilimab or placebo combined with SOX chemotherapy (oxaliplatin + tegafur-gimeracil-oteracil potassium) given before surgery (neoadjuvant) and cadonilimab or placebo combined with SOX…
- Trial name
- NCT07023315
- Testing
- Cadonilimab, SOX chemotherapy
- Where
- 6 sites in China
- Volunteers
- 760 people
- Sponsor
- Akeso
Biliary Tract Cancer
AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer
This is a phase 3 study. All subjects are patients with unresectable locally advanced or metastatic biliary tract cancer (BTC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- Trial name
- NCT06591520
- Testing
- AK112, Gemcitabine, Cisplatin, Durvalumab, Gemcitabine, Cisplatin
- Where
- 2 sites in China
- Volunteers
- 682 people
- Sponsor
- Akeso
Colorectal Cancer With Hepatic Metastases
A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases
An open-label, multicenter, phase Ib/II study of AK112 in combination with VG2025 for advanced colorectal cancer with liver metastases.
- Trial name
- NCT07357220
- Testing
- VG2025, AK112
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Akeso
Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)
This is a randomized, controlled, multi-center phase II/III study. All patients are resectable locally advanced thoracic esophageal squamous cell carcinoma (ESCC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- Trial name
- NCT07263919
- Testing
- Cadonilimab (AK104), Cisplatin, Paclitaxel
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Akeso
Alzheimer' s Disease
A Clinical Trial of AK152 in Healthy Volunteers and Patients With Alzheimer' s Disease
This is a randomized, double-blind phase I clinical trial to evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of AK152 in Healthy Volunteers and Patients with Alzheimer' s Disease.
- Trial name
- NCT07301502
- Testing
- AK152
- Where
- China
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Akeso
Solid Cancer
A Study of AK138D1 in Advanced Malignant Tumors
This is a Phase I clinical trial testing the safety and effectiveness of AK138D1in patients with advanced cancer. The study will enroll up to 200 patients with various types of advanced solid tumors who haven't responded to…
- Trial name
- NCT07281326
- Testing
- AK138D1
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Akeso
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
A Study of Ivonescimab in First-Line ES-SCLC
The goal of this clinical trial is to learn if different combinations of a drug called Ivonescimab, along with chemotherapy and other investigational drugs, are safe and effective for the initial treatment of adults with…
- Trial name
- NCT07245446
- Testing
- Ivonescimab, Cadonilimab, AK117
- Where
- 3 sites in China
- Volunteers
- 180 people
- Sponsor
- Akeso